TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-08-08 am EDT
3765.00 JPY   +0.83%
08/04TAKEDA PHARMACEUTICAL : Quarterly Securities Report for the 1st Quarter
PU
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/01Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Signs 15-Year Lease with BioMed Realty

06/22/2022 | 06:55am EDT

Takeda announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The facility will allow Takeda, the large life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology to support the company in its efforts to advance innovation for patients. The new facility will support Takeda's efforts to redefine the future of work by adopting flexible workspaces to maximize in-person interaction and connection under a flexible and hybrid working model. The company will also expand its existing space in 650 East Kendall to include two additional floors, making Takeda the sole laboratory and office tenant in that building. The agreement with BioMed Realty further expands Takeda's presence in Kendall Square, a hub for life sciences, and is part of the company's long-term strategy to create one Cambridge campus in Kendall Square, unifying Takeda's Global R&D center in Cambridge and co-locating R&D with businesses and other operations. Takeda will eventually transition teams from Central Square to Kendall Square over time. Takeda will maintain a presence in Lexington as its suburban location. The new building is designed with sustainability in mind and will pursue LEED Gold or higher certification. And, as part of this innovative project, Takeda and BioMed Realty have identified shared goals and commitments around occupant wellness, energy and water efficiency, and reduced waste to landfills. Moving to 585 Third Street and expanding the presence in Kendall Square will help Takeda achieve its ambitious environmental goals including net-zero greenhouse gas emissions for scopes 1 and 2 before 2035, and for its entire value chain, including currently estimated scope 3 GHG emissions, before 2040.


© S&P Capital IQ 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
08/04TAKEDA PHARMACEUTICAL : Quarterly Securities Report for the 1st Quarter
PU
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/01Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy
MT
07/29Takeda Pharmaceutical's Fiscal Q1 Attributable Profit Slides 24%
MT
07/28TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q1 2023 Earnings Call, Jul 28, 2022
CI
07/28Takeda Posts Higher Fiscal Q1 Core Profit, Revenue
MT
07/28Takeda Pharmaceutical's First-Quarter Net Profit Fell 24% From High Base
DJ
07/28Takeda sees quarterly profit drop 39% after last year's one-time gains
RE
07/28Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Managem..
BU
07/28Takeda Pharmaceutical Company Limited Announces Dividend Guidance for Second Quarter an..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 756 B 27 898 M 27 898 M
Net income 2023 306 B 2 274 M 2 274 M
Net Debt 2023 3 038 B 22 566 M 22 566 M
P/E ratio 2023 19,0x
Yield 2023 4,78%
Capitalization 5 821 B 43 237 M 43 237 M
EV / Sales 2023 2,36x
EV / Sales 2024 2,28x
Nbr of Employees 47 347
Free-Float 96,8%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 765,00 JPY
Average target price 4 561,33 JPY
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED19.03%42 640
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-16.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068